Related Experiment Video
Updated: Jul 27, 2026
Dextran Enhances the Lentiviral Transduction Efficiency of Murine and Human Primary NK Cells
Published on: January 15, 2018
Extracellular vesicles derived from immortalized human natural killer cell line NK3.3 as a novel therapeutic for
Emily C Matchett1, Jacki Kornbluth1,2
1Department of Pathology, Saint Louis University School of Medicine, St. Louis, MO, United States.
Introduction:
Over the last decade, there have been many advancements in the therapeutic treatment of multiple myeloma (MM), including the use of natural killer (NK) cells. However, despite promising results from clinical trials, there are concerns over the use of NK cell-based therapy. Cells often undergo growth arrest, limiting their experimental utility; donor cells are extremely heterogeneous, resulting in content variability; and patients receiving allogeneic cells are at risk for graft-versus-host disease and/or cytokine release syndrome. Extracellular vesicles (EVs) have emerged as a new natural therapeutic tool. EVs are known to carry cargo derived from the parent cell from which they originate. NK cells play an important role in the innate immune system, targeting and killing tumor cells. This has led many researchers to isolate EVs from NK cells for their cytotoxic potential.
Methods:
In this study, we isolated EVs from the NK cell line, NK3.3, which was derived from the peripheral blood of a healthy donor. Currently, it is the only normal human NK cell line reported with all the functional characteristics of healthy NK cells. To address the issue of growth arrest, we immortalized NK3.3 cells with lentivirus encoding the catalytic subunit of human telomerase htert (NK3.3-LTV). EVs from these cells were isolated using a modified polyethylene glycol (PEG)-acetate precipitation protocol to simplify processing and increase EV yield.
Results And Conclusions:
We demonstrated that NK3.3-LTV EVs target both sensitive and drug-resistant MM cell lines as well as primary patient MM cells in vitro, decreasing proliferation and inducing apoptotic cell death as well as or better than EVs from non-immortalized cells with no toxicity towards normal cells. This study is the first step towards developing an immunotherapeutic product designed to treat patients with relapsed/refractory MM.
Insights
Extracellular vesicles derived from immortalized natural killer (NK) cells show promise for treating multiple myeloma (MM). These NK cell-derived EVs effectively target and reduce MM cell growth without harming normal cells, offering a potential new therapy.
Area of Science:
- Immunology
- Cell Biology
- Biotechnology
Background:
- Advancements in multiple myeloma (MM) therapy include natural killer (NK) cell-based treatments.
- NK cell therapy faces challenges like growth arrest, cellular heterogeneity, and adverse effects such as graft-versus-host disease.
- Extracellular vesicles (EVs) are emerging as therapeutic tools, carrying cargo from their parent cells and exhibiting cytotoxic potential.
Purpose of the Study:
- To develop a novel therapeutic strategy for relapsed/refractory multiple myeloma (MM) using extracellular vesicles (EVs) derived from immortalized NK cells.
- To overcome limitations of NK cell therapy, such as growth arrest and heterogeneity, by utilizing EVs.
Main Methods:
- Isolated EVs from the NK3.3 cell line, a normal human NK cell line.
- Immortalized NK3.3 cells using lentivirus encoding human telomerase reverse transcriptase (hTERT) to create NK3.3-LTV cells, addressing growth arrest.
- Utilized a modified polyethylene glycol (PEG)-acetate precipitation protocol for simplified EV isolation and increased yield.
Main Results:
- NK3.3-LTV EVs demonstrated efficacy against both sensitive and drug-resistant MM cell lines and primary patient cells in vitro.
- EVs from immortalized NK cells reduced MM cell proliferation and induced apoptotic cell death.
- No toxicity was observed towards normal cells, indicating a favorable safety profile.
Conclusions:
- EVs derived from immortalized NK cells represent a viable therapeutic candidate for multiple myeloma (MM).
- This approach offers a potential alternative to direct NK cell therapy, mitigating associated risks.
- Further development of NK3.3-LTV EVs could lead to an effective immunotherapeutic product for relapsed/refractory MM patients.
